Group 1 - The core viewpoint of the news is that Shouyao Holdings has seen a significant increase in its stock price, rising by 5.01% to reach 46.57 yuan per share, with a total market capitalization of 6.926 billion yuan [1] - Shouyao Holdings, established on April 19, 2016, specializes in the research and development of small molecule anti-tumor drugs, with its main business revenue entirely derived from technology development and services [1] - The trading volume for Shouyao Holdings was 62.3524 million yuan, with a turnover rate of 2.14% [1] Group 2 - According to data, a fund under Jianxin Fund has Shouyao Holdings as one of its top ten holdings, specifically Jianxin High-end Medical Stock A (004683), which held 121,900 shares, accounting for 3.53% of the fund's net value [2] - The fund has realized a floating profit of approximately 270,700 yuan from its investment in Shouyao Holdings [2] - Jianxin High-end Medical Stock A has achieved a year-to-date return of 16.98% and a one-year return of 23.22%, ranking 2964 out of 4222 and 3576 out of 3802 in its category, respectively [2] Group 3 - The fund manager of Jianxin High-end Medical Stock A is Pan Longling, who has been in the position for 9 years and 172 days, with the fund's total asset size currently at 160 million yuan [3] - During Pan Longling's tenure, the best fund return was 60.05%, while the worst return was -30.58% [3]
首药控股股价涨5.01%,建信基金旗下1只基金重仓,持有12.19万股浮盈赚取27.07万元